Glasgow prognostic score is a prognosis predictor for patients with endometrial cancer

Masayuki Saijo, Keiichiro Nakamura, Hisashi Masuyama, Naoyuki Ida, Tomoko Haruma, Tomoyuki Kusumoto, Noriko Seki, Yuji Hiramatsu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective This study investigated whether the inflammation-based Glasgow prognostic score (GPS) predicted the prognosis of patients with endometrial cancer (EC) in terms of progression-free survival (PFS) and overall survival (OS). Study design Pretreatment GPS was examined to determine the correlations with recurrence and survival in 431 patients with EC. Statistical analyses were performed using the Mann–Whitney U test. PFS and OS were analyzed using the Kaplan–Meier method. Cox's proportional hazard regression was used for univariate and multivariate analyses. Results Median PFS and OS were 49.7 and 52.7 months, respectively. The follow-up range was 1 to 140 months. Kaplan–Meier analysis revealed that patients with EC cancer and high GPS (GPS 2) had a shorter PFS and OS than those with lower GPS (GPS 0 + 1) (PFS: P < 0.001; OS; P < 0.001). On multivariate analysis, GPS (GPS 2) was an independent predictor of both recurrence (P < 0.001) and survival (P < 0.001) for all cases of EC. Conclusion GPS can be useful as an indicator of poor prognosis in patients with EC.

Original languageEnglish
Pages (from-to)355-359
Number of pages5
JournalEuropean Journal of Obstetrics Gynecology and Reproductive Biology
Volume210
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Endometrial Neoplasms
Disease-Free Survival
Survival
Multivariate Analysis
Recurrence
Inflammation
Neoplasms

Keywords

  • Endometrial cancer
  • Glasgow prognostic score
  • Poor prognosis

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Cite this

Glasgow prognostic score is a prognosis predictor for patients with endometrial cancer. / Saijo, Masayuki; Nakamura, Keiichiro; Masuyama, Hisashi; Ida, Naoyuki; Haruma, Tomoko; Kusumoto, Tomoyuki; Seki, Noriko; Hiramatsu, Yuji.

In: European Journal of Obstetrics Gynecology and Reproductive Biology, Vol. 210, 01.03.2017, p. 355-359.

Research output: Contribution to journalArticle

Saijo, Masayuki ; Nakamura, Keiichiro ; Masuyama, Hisashi ; Ida, Naoyuki ; Haruma, Tomoko ; Kusumoto, Tomoyuki ; Seki, Noriko ; Hiramatsu, Yuji. / Glasgow prognostic score is a prognosis predictor for patients with endometrial cancer. In: European Journal of Obstetrics Gynecology and Reproductive Biology. 2017 ; Vol. 210. pp. 355-359.
@article{c46985a8936844a1b19cfaad6f1e9b09,
title = "Glasgow prognostic score is a prognosis predictor for patients with endometrial cancer",
abstract = "Objective This study investigated whether the inflammation-based Glasgow prognostic score (GPS) predicted the prognosis of patients with endometrial cancer (EC) in terms of progression-free survival (PFS) and overall survival (OS). Study design Pretreatment GPS was examined to determine the correlations with recurrence and survival in 431 patients with EC. Statistical analyses were performed using the Mann–Whitney U test. PFS and OS were analyzed using the Kaplan–Meier method. Cox's proportional hazard regression was used for univariate and multivariate analyses. Results Median PFS and OS were 49.7 and 52.7 months, respectively. The follow-up range was 1 to 140 months. Kaplan–Meier analysis revealed that patients with EC cancer and high GPS (GPS 2) had a shorter PFS and OS than those with lower GPS (GPS 0 + 1) (PFS: P < 0.001; OS; P < 0.001). On multivariate analysis, GPS (GPS 2) was an independent predictor of both recurrence (P < 0.001) and survival (P < 0.001) for all cases of EC. Conclusion GPS can be useful as an indicator of poor prognosis in patients with EC.",
keywords = "Endometrial cancer, Glasgow prognostic score, Poor prognosis",
author = "Masayuki Saijo and Keiichiro Nakamura and Hisashi Masuyama and Naoyuki Ida and Tomoko Haruma and Tomoyuki Kusumoto and Noriko Seki and Yuji Hiramatsu",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.ejogrb.2017.01.024",
language = "English",
volume = "210",
pages = "355--359",
journal = "European Journal of Obstetrics and Gynecology and Reproductive Biology",
issn = "0028-2243",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Glasgow prognostic score is a prognosis predictor for patients with endometrial cancer

AU - Saijo, Masayuki

AU - Nakamura, Keiichiro

AU - Masuyama, Hisashi

AU - Ida, Naoyuki

AU - Haruma, Tomoko

AU - Kusumoto, Tomoyuki

AU - Seki, Noriko

AU - Hiramatsu, Yuji

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Objective This study investigated whether the inflammation-based Glasgow prognostic score (GPS) predicted the prognosis of patients with endometrial cancer (EC) in terms of progression-free survival (PFS) and overall survival (OS). Study design Pretreatment GPS was examined to determine the correlations with recurrence and survival in 431 patients with EC. Statistical analyses were performed using the Mann–Whitney U test. PFS and OS were analyzed using the Kaplan–Meier method. Cox's proportional hazard regression was used for univariate and multivariate analyses. Results Median PFS and OS were 49.7 and 52.7 months, respectively. The follow-up range was 1 to 140 months. Kaplan–Meier analysis revealed that patients with EC cancer and high GPS (GPS 2) had a shorter PFS and OS than those with lower GPS (GPS 0 + 1) (PFS: P < 0.001; OS; P < 0.001). On multivariate analysis, GPS (GPS 2) was an independent predictor of both recurrence (P < 0.001) and survival (P < 0.001) for all cases of EC. Conclusion GPS can be useful as an indicator of poor prognosis in patients with EC.

AB - Objective This study investigated whether the inflammation-based Glasgow prognostic score (GPS) predicted the prognosis of patients with endometrial cancer (EC) in terms of progression-free survival (PFS) and overall survival (OS). Study design Pretreatment GPS was examined to determine the correlations with recurrence and survival in 431 patients with EC. Statistical analyses were performed using the Mann–Whitney U test. PFS and OS were analyzed using the Kaplan–Meier method. Cox's proportional hazard regression was used for univariate and multivariate analyses. Results Median PFS and OS were 49.7 and 52.7 months, respectively. The follow-up range was 1 to 140 months. Kaplan–Meier analysis revealed that patients with EC cancer and high GPS (GPS 2) had a shorter PFS and OS than those with lower GPS (GPS 0 + 1) (PFS: P < 0.001; OS; P < 0.001). On multivariate analysis, GPS (GPS 2) was an independent predictor of both recurrence (P < 0.001) and survival (P < 0.001) for all cases of EC. Conclusion GPS can be useful as an indicator of poor prognosis in patients with EC.

KW - Endometrial cancer

KW - Glasgow prognostic score

KW - Poor prognosis

UR - http://www.scopus.com/inward/record.url?scp=85010391272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010391272&partnerID=8YFLogxK

U2 - 10.1016/j.ejogrb.2017.01.024

DO - 10.1016/j.ejogrb.2017.01.024

M3 - Article

C2 - 28129563

AN - SCOPUS:85010391272

VL - 210

SP - 355

EP - 359

JO - European Journal of Obstetrics and Gynecology and Reproductive Biology

JF - European Journal of Obstetrics and Gynecology and Reproductive Biology

SN - 0028-2243

ER -